IBIO vs CLYM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

IBIO

52.5
AI Score
VS
CLYM Wins

CLYM

63.4
AI Score

Investment Advisor Scores

IBIO

53score
Recommendation
HOLD

CLYM

63score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IBIO CLYM Winner
Net Income -32.84M -27.22M CLYM
Operating Income -35.14M -30.57M CLYM
ROE -38.3% -11.4% CLYM
ROA -33.1% -11.1% CLYM
Total Assets 99.11M 246.29M CLYM
Cash 56.40M 44.11M IBIO
Current Ratio 7.85 31.45 CLYM
Free Cash Flow -23.80M -25.18M IBIO

Relative Price Performance (Last 90 Days)

IBIO 1M: -40.2% · 3M: -50.5% CLYM 1M: -14.3% · 3M: -20.3%

Current Technical Phase

IBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -14.0%), weak momentum, RSI 25

RSI (14): 24.9 · Price: $0.72

CLYM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.1%), weak momentum, RSI 38

RSI (14): 38.2 · Price: $10.19

Fundamentals Snapshot

Metric IBIO CLYM
Market Cap — —
Forward P/E -2.3 -10.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -1.0% 0.0%
Gross Margin 1.0% —
Operating Margin -301.4% 0.0%
EPS -0.32 -0.80
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLYM is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.